LEAWOOD, Kan., April 25, 2016 /PRNewswire/ -- Aratana
Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company
focused on the licensing, development and commercialization of
innovative biopharmaceutical products for companion animals will
host a conference call today, Monday, April
25, 2016, at 6:00 p.m. ET to
update the investment community regarding the strategic
collaboration with Elanco Animal Health, a division of Eli Lilly
and Company (NYSE: LLY) that was announced this afternoon.
Additional information is available in a Form 8-K filed with the
SEC on April 25, 2016.
Interested participants and investors may access the audio
webcast or use the conference call dial-in:
1 (866) 364-3820 (U.S.)
1 (855) 669-9657 (Canada)
1 (412) 902-4210 (International)
A replay of the teleconference will be available the same day of
the event by approximately 9 p.m. ET
and an audio webcast will be accessible for 90 days in the Aratana
Investor Room. For a replay of the call, use the below dial-in and
conference ID 10085359:
1 (877) 344-7529 (U.S.)
1 (855) 669-9658 (Canada)
1 (412) 317-0088 (International)
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on licensing, developing and
commercializing innovative pharmaceutical products for dogs and
cats. Aratana believes that it can leverage the investment in the
human pharmaceutical industry to bring therapeutics to pets in a
capital and time efficient manner. The Company has multiple
products approved by the Food and Drug Administration's Center for
Veterinary Medicine or licensed by the United States Department of
Agriculture. The Company's pipeline includes therapeutic candidates
targeting pain, inappetence, cancer, viral diseases, allergy and
other serious, unmet or underserved medical needs. Aratana
believes providing innovative options to veterinarians and pet
owners will help manage pets' medical needs safely and effectively,
resulting in longer and improved quality of life for pets. For more
information, please visit www.aratana.com.
Contacts
For investor inquires:
Craig Tooman
ctooman@aratana.com
(913) 353-1026
For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050
Logo - http://photos.prnewswire.com/prnh/20160425/359503LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-discuss-global-strategic-collaboration-with-elanco-animal-health-300256866.html
SOURCE Aratana Therapeutics, Inc.